Repligen Corporation

RGEN

US7599161095

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
166.6 ^USD	+0.56%		+6.01%	-7.35%

Apr. 08	RBC Cuts Price Target on Repligen to $221 From $225, Keeps Outperform Rating	MT
Mar. 20	Transcript : Repligen Corporation Presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum, Mar-20-2024 03:00 PM

Repligen Corporation announced that it has received $290.1 million in funding

December 13, 2023

On December 14, 2023, Repligen Corporation closed the transaction.

Latest news about Repligen Corporation

RBC Cuts Price Target on Repligen to $221 From $225, Keeps Outperform Rating	Apr. 08	MT
Transcript : Repligen Corporation Presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum, Mar-20-2024 03:00 PM	Mar. 20
Repligen Corporation Appoints Maggie A. Pax as Board of Directors	Mar. 19	CI
Repligen Insider Sold Shares Worth $681,348, According to a Recent SEC Filing	Mar. 13	MT
Repligen Insider Sold Shares Worth $3,298,632, According to a Recent SEC Filing	Mar. 12	MT
Repligen Insider Sold Shares Worth $866,204, According to a Recent SEC Filing	Feb. 27	MT
UBS Adjusts Repligen Price Target to $225 From $211, Maintains Buy Rating	Feb. 22	MT
Deutsche Bank Adjusts Repligen Price Target to $180 From $175, Maintains Hold Rating	Feb. 22	MT
RBC Raises Price Target on Repligen to $225 From $200, Keeps Outperform Rating	Feb. 22	MT
Sector Update: Health Care Stocks Flat to Lower Premarket Wednesday	Feb. 21	MT
Sector Update: Health Care	Feb. 21	MT
Transcript : Repligen Corporation, Q4 2023 Earnings Call, Feb 21, 2024	Feb. 21
Repligen Q4 Adjusted Earnings, Revenue Decline; Issues 2024 Guidance; Shares Fall Premarket	Feb. 21	MT
Sartorius falls - outlook from Repligen disappointed	Feb. 21	DP
(RGEN) REPLIGEN CORPORATION Expects Fiscal Year 2024 EPS Range $1.42 - $1.49	Feb. 21	MT
Earnings Flash (RGEN) REPLIGEN CORPORATION Reports Q4 Revenue $155.7M, vs. Street Est of $156.3M	Feb. 21	MT
Earnings Flash (RGEN) REPLIGEN CORPORATION Reports Q4 EPS $0.33, vs. Street Est of $0.34	Feb. 21	MT
Repligen Corporation Provides Earnings Guidance for the Year 2024	Feb. 21	CI
Repligen Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21	CI
Repligen Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 21	CI
Stocks Decline Pre-Bell as Fed Outlook, Rates Weigh; Asia Mixed, Europe Mostly Up	Feb. 21	MT
North American Morning Briefing : Stock Futures -2-	Feb. 21	DJ
Transcript : Repligen Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 02:15 PM	Jan. 09
Deutsche Bank Adjusts Repligen Price Target to $175 From $150, Maintains Hold Rating	Dec. 18	MT
UBS Adjusts Repligen Price Target to $211 From $170, Maintains Buy Rating	Dec. 15	MT

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Companyâs chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Companyâs TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-04-30 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Repligen Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

166.6 USD

Average target price

210.9 USD

Spread / Average Target

+26.59%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
REPLIGEN CORPORATION	-7.35%	9.3B
ABBOTT LABORATORIES	-2.31%	187B
MEDTRONIC PLC	-3.20%	106B
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B
DEXCOM, INC.	+0.20%	49.45B
CENCORA, INC.	+17.29%	48B
HOYA CORPORATION	+4.06%	40.84B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B
TERUMO CORPORATION	+12.96%	24.62B

Other Medical Equipment, Supplies & Distribution